New combo therapy aims to control diabetes without side effects
NCT ID NCT07365358
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study compares two different drug combinations for people with type 2 diabetes whose blood sugar is not well controlled with metformin and sitagliptin. About 200 adults will receive either empagliflozin or glimepiride added to their current treatment. The goal is to see which combination helps achieve stable blood sugar levels without causing weight gain or dangerously low blood sugar.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIABETE TYPE 2 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Kyung Hee University Hospital at Gangdong
Seoul, South Korea
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Gamifying exercise: could a phone app outperform traditional programs for obesity and diabetes?
- Can your DNA predict how you respond to a diabetes drug?
- Antioxidant-rich diets may fight inflammation in type 2 diabetes — a study investigates
- Can two experimental pills work together safely? a trial seeks answers
- Could meal kits and text messages help curb diabetes in Food-Insecure communities?
- Walking downhill may boost heart health and strength in type 2 diabetes